Etrasimod for Teens With Moderate to Severe Ulcerative Colitis
Tests etrasimod in adolescents aged 12 to 17 with ulcerative colitis.
Key facts
- Who runs it
- Pfizer
- Where
- Abilene, Boston, Chicago, Cleveland, Fort Worth, Garden Grove, Little Rock, Loma Linda, Orlando, Royal Oak, San Bernardino, and San Francisco, United StatesSee the 21 sitesAlso in 6 other countries, 29 sites
- Trial code
- Registry title
- A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 36 people, planned
- Started
- 16 Dec 2022
- Expected to end
- 10 Jul 2033
- Type of study
- Interventional
- Treatments tested
- Etrasimod
- Record updated
- 27 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for teenagers with moderately to severely active ulcerative colitis. All take etrasimod.
- Age
- 12 to 17 years
- Sex
- All sexes
- Disease stage
- Ulcerative colitis that is moderately to severely active
- Earlier treatment
- People can join while taking a therapeutic dose of select ulcerative colitis treatments.
Main reasons for not taking part
- Severe extensive colitis
- Crohn's disease or indeterminate colitis, or a fistula linked to Crohn's disease
- Microscopic colitis, ischemic colitis, or infectious colitis
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Have a diagnosis of ulcerative colitis (UC) that is moderately to severely active
- Participants are permitted to be receiving a therapeutic dose of select UC therapies
Who cannot take part
- Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history of a fistula consistent with CD
- Severe extensive colitis
- Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 17 years old?
Where in United States
Also in 6 other countries, 29 sites
- ACT-Midwest G1Abilene, United StatesTaking people
- Boston Children's HospitalBoston, United StatesTaking people
- University of Chicago Medical CenterChicago, United StatesTaking people
- University Hospitals Cleveland Medical Center Rainbow Babies & Children's HospitalCleveland, United StatesTaking people
- University Hospitals Cleveland Medical Center*Cleveland, United StatesTaking people
- Cook Children's Health Care System-Dodson Specialty ClinicsFort Worth, United StatesTaking people
- Cook Children's Medical CenterFort Worth, United StatesTaking people
- Valley View Wellness Medical CenterGarden Grove, United StatesTaking people
- Arkansas Children'sLittle Rock, United StatesNot yet recruiting
- Arkansas Children's (IP Address)Little Rock, United StatesNot yet recruiting
- Loma Linda Children's HospitalLoma Linda, United StatesNot yet recruiting
- Loma Linda University Clinical Trial CenterLoma Linda, United StatesNot yet recruiting
- Loma Linda University Eye InstituteLoma Linda, United StatesNot yet recruiting
- Loma Linda University Medical CenterLoma Linda, United StatesNot yet recruiting
- Loma Linda University Pediatric ClinicsLoma Linda, United StatesNot yet recruiting
- Arnold Palmer Hospital - Center for Digestive Health and NutritionOrlando, United StatesTaking people
- William Beaumont Hospital/Corewell Health - EastRoyal Oak, United StatesTaking people
- William Beaumont Hospitals Reference LaboratoryRoyal Oak, United StatesTaking people
- Loma Linda University Children's Hospital Pediatric Specialty ClinicsSan Bernardino, United StatesNot yet recruiting
- University of California San FranciscoSan Francisco, United StatesTaking people
- University of California,San Francisco Pediatric ClinicalResearch Center (PCRC)San Francisco, United StatesTaking people
About the trial
What the trial wants to find out
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to < 18 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment).
The group in the trial
- EtrasimodTreatment being tested
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- An Open-Label, Single-Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- Plain-language title
- Etrasimod for Teens With Moderate to Severe Ulcerative ColitisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05287126, who can take part
- Record updated
- 27 October 2026